Structure and activation of rhodopsin

Acta Pharmacologica Sinica

Volumn 33, Issue 3, 2012, Pages 291-299

  Zhou, X Edward ^a   Melcher, Karsten ^a   Xu, H Eric ^a,b  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

crystal structure; G protein coupled receptor (GPCR); photoactivation; rhodopsin; transduction

Indexed keywords

G PROTEIN COUPLED RECEPTOR; RHODOPSIN;

CRYSTAL STRUCTURE; HUMAN; NONHUMAN; PHOTORECEPTOR; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; VISUAL SYSTEM; X RAY CRYSTALLOGRAPHY;

ANIMALS; CRYSTALLOGRAPHY, X-RAY; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; RECEPTORS, G-PROTEIN-COUPLED; RHODOPSIN; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84863289680     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.171     Document Type: Review

References (71)

1. Hubbard R, Kropf A. The action of light on rhodopsin. Proc Natl Acad Sci U S A 1958; 44: 130-9.
2. Fredriksson R, Lagerström MC, Lundin LG, Schiöth HB. The G-proteincoupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 2003; 63: 17.
3. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000; 289: 739-45. (Pubitemid 30650186)
4. Li J, Edwards PC, Burghammer M, Villa C, Schertler GF. Structure of bovine rhodopsin in a trigonal crystal form. J Mol Biol 2004; 343: 1409-38. (Pubitemid 39387834)
5. Standfuss J, Xie G, Edwards PC, Burghammer M, Oprian DD, Schertler GF. Crystal structure of a thermally stable rhodopsin mutant. J Mol Biol 2007; 372: 1179-88. (Pubitemid 47381449)
6. Okada T, Sugihara M, Bondar AN, Elstner M, Entel P, Buss V. The retinal conformation and its environment in rhodopsin in light of a new 2.2 Å crystal structure. J Mol Biol 2004; 342: 571-83. (Pubitemid 39149759)
7. Salom D, Lodowski DT, Stenkamp RE, Le Trong I, Golczak M, Jastrzebska B, et al. Crystal structure of a photoactivated deprotonated intermediate of rhodopsin. Proc Natl Acad Sci U S A 2006; 103: 16123-8. (Pubitemid 44715162)
8. Standfuss J, Edwards PC, D'Antona A, Fransen M, Xie G, Oprian DD, et al. The structural basis of agonist-induced activation in constitutively active rhodopsin. Nature 2011; 471: 656-60.
9. Park JH, Scheerer P, Hofmann KP, Choe HW, Ernst OP. Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 2008; 454: 183-7. (Pubitemid 351969893)
10. Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krauss N, Choe HW, et al. Crystal structure of opsin in its G-protein-interacting conformation. Nature 2008; 455: 497-502.
11. Choe HW, Kim YJ, Park JH, Morizumi T, Pai EF, Krauss N, et al. Crystal structure of metarhodopsin II. Nature 2011; 471: 651-5.
12. Brown MF, Martinez-Mayorga K, Nakanishi K, Salgado GF, Struts AV. Retinal conformation and dynamics in activation of rhodopsin illuminated by solid-state H NMR spectroscopy. Photochem Photobiol 2009; 85: 442-53.
13. Jastrzebska B, Tsybovsky Y, Palczewski K. Complexes between photoactivated rhodopsin and transducin: progress and questions. Biochem J 2010; 428: 1-10.
14. Bosch L, Iarriccio L, Garriga P. New prospects for drug discovery from structural studies of rhodopsin. Curr Pharm Des 2005; 11: 2243-56. (Pubitemid 40872714)
15. Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, Henderson R, et al. Structure of a beta1-adrenergic G-proteincoupled receptor. Nature 2008; 454: 486-91.
16. Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008; 322: 1211-7.
17. Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, et al. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 2007; 450: 383-7. (Pubitemid 350126755)
18. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007; 318: 1258-65. (Pubitemid 350172884)
19. Rasmussen SG, Choi HJ, Fung JJ, Pardon E, Casarosa P, Chae PS, et al. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 2011; 469: 175-80.
20. Rosenbaum DM, Zhang C, Lyons JA, Holl R, Aragao D, Arlow DH, et al. Structure and function of an irreversible agonist: beta(2) adrenoceptor complex. Nature 2011; 469: 236-40.
21. Rasmussen SG, Devree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, et al. Crystal structure of the beta(2) adrenergic receptor-Gs protein complex. Nature 2011; 477: 549-55.
22. Kaushal S, Ridge KD, Khorana HG. Structure and function in rhodopsin: the role of asparagine-linked glycosylation. Proc Natl Acad Sci U S A 1994; 91: 4024-8. (Pubitemid 24139565)
23. Sung CH, Davenport CM, Hennessey JC, Maumenee IH, Jacobson SG, Heckenlively JR, et al. Rhodopsin mutations in autosomal dominant retinitis pigmentosa. Proc Natl Acad Sci U S A 1991; 88: 6481-5. (Pubitemid 21914970)
24. Al-Maghtheh M, Gregory C, Inglehearn C, Hardcastle A, Bhattacharya S. Rhodopsin mutations in autosomal dominant retinitis pigmentosa. Hum Mutat 1993; 2: 249-55. (Pubitemid 23231499)
25. Karnik SS, Khorana HG. Assembly of functional rhodopsin requires a disulfide bond between cysteine residues 110 and 187. J Biol Chem 1990; 265: 17520-4.
26. Janz JM, Fay JF, Farrens DL. Stability of dark state rhodopsin is mediated by a conserved ion pair in intradiscal loop E-2. J Biol Chem 2003; 278: 16982-91. (Pubitemid 36799573)
27. Ohguro H, Rudnicka-Nawrot M, Buczylko J, Zhao X, Taylor JA, Walsh KA, et al. Structural and enzymatic aspects of rhodopsin phosphorylation. J Biol Chem 1996; 271: 5215-24. (Pubitemid 26075019)
28. Chabre M. Trigger and amplification mechanisms in visual phototransduction. Annu Rev Biophys Biophys Chem 1985; 14: 331-60.
29. Rao VR, Oprian DD. Activating mutations of rhodopsin and other G protein-coupled receptors. Annu Rev Biophys Biomol Struct 1996; 25: 287-314. (Pubitemid 26197501)
30. Nakamichi H, Okada T. Crystallographic analysis of primary visual photochemistry. Angew Chem Int Ed Engl 2006; 45: 4270-3. (Pubitemid 44105630)
31. Nakamichi H, Okada T. Local peptide movement in the photoreaction intermediate of rhodopsin. Proc Natl Acad Sci U S A 2006; 103: 12729-34. (Pubitemid 44298629)
32. Ruprecht JJ, Mielke T, Vogel R, Villa C, Schertler GF. Electron crystallography reveals the structure of metarhodopsin I. EMBO J 2004; 23: 3609-20. (Pubitemid 39336283)
33. Ridge KD, Palczewski K. Visual rhodopsin sees the light: structure and mechanism of G protein signaling. J Biol Chem 2007; 282: 9297-301. (Pubitemid 47104561)
34. Yang T, Snider BB, Oprian DD. Synthesis and characterization of a novel retinylamine analog inhibitor of constitutively active rhodopsin mutants found in patients with autosomal dominant retinitis pigmentosa. Proc Natl Acad Sci U S A 1997; 94: 13559-64. (Pubitemid 28009622)
35. Keen TJ, Inglehearn CF, Lester DH, Bashir R, Jay M, Bird AC, et al. Autosomal dominant retinitis pigmentosa: four new mutations in rhodopsin, one of them in the retinal attachment site. Genomics 1991; 11: 199-205.
36. Reig C, Antich J, Gean E, Garcia-Sandoval B, Ramos C, Ayuso C, et al. Identification of a novel rhodopsin mutation (Met-44-Thr) in a simplex case of retinitis pigmentosa. Hum Genet 1994; 94: 283-6. (Pubitemid 24262207)
37. Vaithinathan R, Berson EL, Dryja TP. Further screening of the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa. Genomics 1994; 21: 461-3. (Pubitemid 24172436)
38. Dryja TP, McEvoy JA, McGee TL, Berson EL. Novel rhodopsin mutations Gly114Val and Gln184Pro in dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci 2000; 41: 3124-7.
39. Dryja TP. Doyne Lecture. Rhodopsin and autosomal dominant retinitis pigmentosa. Eye (Lond) 1992; 6: 1-10.
40. Dryja TP, Hahn LB, Cowley GS, McGee TL, Berson EL. Mutation spectrum of the rhodopsin gene among patients with autosomal dominant retinitis pigmentosa. Proc Natl Acad Sci U S A 1991; 88: 9370-4. (Pubitemid 21915633)
41. Souied E, Gerber S, Rozet JM, Bonneau D, Dufier JL, Ghazi I, et al. Five novel missense mutations of the rhodopsin gene in autosomal dominant retinitis pigmentosa. Hum Mol Genet 1994; 3: 1433-4. (Pubitemid 24255489)
42. Farrar GJ, Kenna P, Redmond R, Shiels D, McWilliam P, Humphries MM, et al. Autosomal dominant retinitis pigmentosa: a mutation in codon 178 of the rhodopsin gene in two families of Celtic origin. Genomics 1991; 11: 1170-1.
43. Matias-Florentino M, Ayala-Ramirez R, Graue-Wiechers F, Zenteno JC. Molecular screening of rhodopsin and peripherin/RDS genes in Mexican families with autosomal dominant retinitis pigmentosa. Curr Eye Res 2009; 34: 1050-6.
44. Liu X, Garriga P, Khorana HG. Structure and function in rhodopsin: correct folding and misfolding in two point mutants in the intradiscal domain of rhodopsin identified in retinitis pigmentosa. Proc Natl Acad Sci U S A 1996; 93: 4554-9. (Pubitemid 26162800)
45. Macke JP, Davenport CM, Jacobson SG, Hennessey JC, Gonzalez-Fernandez F, Conway BP, et al. Identification of novel rhodopsin mutations responsible for retinitis pigmentosa: implications for the structure and function of rhodopsin. Am J Hum Genet 1993; 53: 80-9. (Pubitemid 23313738)
46. Farrar GJ, Findlay JB, Kumar-Singh R, Kenna P, Humphries MM, Sharpe E, et al. Autosomal dominant retinitis pigmentosa: a novel mutation in the rhodopsin gene in the original 3q linked family. Hum Mol Genet 1992; 1: 769-71.
47. Haim M, Grundmann K, Gal A, Rosenberg T. Novel rhodopsin mutation (M216R) in a Danish family with autosomal dominant retinitis pigmentosa. Ophthalmic Genet 1996; 17: 193-7. (Pubitemid 27067559)
48. Al-Maghtheh M, Inglehearn C, Lunt P, Jay M, Bird A, Bhattacharya S. Two new rhodopsin transversion mutations (L40R; M216K) in families with autosomal dominant retinitis pigmentosa. Hum Mutat 1994; 3: 409-10. (Pubitemid 24198838)
49. Sieving PA, Richards JE, Naarendorp F, Bingham EL, Scott K, Alpern M. Dark-light: model for nightblindness from the human rhodopsin Gly-90 → Asp mutation. Proc Natl Acad Sci U S A 1995; 92: 880-4.
50. Dryja TP, Berson EL, Rao VR, Oprian DD. Heterozygous missense mutation in the rhodopsin gene as a cause of congenital stationary night blindness. Nat Genet 1993; 4: 280-3. (Pubitemid 23205177)
51. Nakayama TA, Khorana HG. Mapping of the amino acids in membrane-embedded helices that interact with the retinal chromophore in bovine rhodopsin. J Biol Chem 1991; 266: 4269-75. (Pubitemid 21909351)
52. Hwa J, Garriga P, Liu X, Khorana HG. Structure and function in rhodopsin: packing of the helices in the transmembrane domain and folding to a tertiary structure in the intradiscal domain are coupled. Proc Natl Acad Sci U S A 1997; 94: 10571-6. (Pubitemid 27430775)
53. Sheffield VC, Fishman GA, Beck JS, Kimura AE, Stone EM. Identification of novel rhodopsin mutations associated with retinitis pigmentosa by GC-clamped denaturing gradient gel electrophoresis. Am J Hum Genet 1991; 49: 699-706. (Pubitemid 21891716)
54. Natochin M, Gasimov KG, Moussaif M, Artemyev NO. Rhodopsin determinants for transducin activation: a gain-of-function approach. J Biol Chem2003; 278: 37574-81.
55. Fuchs S, Kranich H, Denton MJ, Zrenner E, Bhattacharya SS, Humphries P, et al. Three novel rhodopsin mutations (C110F, L131P, A164V) in patients with autosomal dominant retinitis pigmentosa. Hum Mol Genet 1994; 3: 1203. (Pubitemid 24211980)
56. Richards JE, Scott KM, Sieving PA. Disruption of conserved rhodopsin disulfide bond by Cys187Tyr mutation causes early and severe autosomal dominant retinitis pigmentosa. Ophthalmology 1995; 102: 669-77.
57. Hwa J, Klein-Seetharaman J, Khorana HG. Structure and function in rhodopsin: Mass spectrometric identification of the abnormal intradiscal disulfide bond in misfolded retinitis pigmentosa mutants. Proc Natl Acad Sci U S A 2001; 98: 4872-6. (Pubitemid 32397049)
58. Huber T, Botelho AV, Beyer K, Brown MF. Membrane model for the G-protein-coupled receptor rhodopsin: hydrophobic interface and dynamical structure. Biophys J 2004; 86: 2078-100. (Pubitemid 38524399)
59. Rodriguez JA, Herrera CA, Birch DG, Daiger SP. A leucine to arginine amino acid substitution at codon 46 of rhodopsin is responsible for a severe form of autosomal dominant retinitis pigmentosa. Hum Mutat 1993; 2: 205-13. (Pubitemid 23205194)
60. Sung CH, Schneider BG, Agarwal N, Papermaster DS, Nathans J. Functional heterogeneity of mutant rhodopsins responsible for auto somal dominant retinitis pigmentosa. Proc Natl Acad Sci U S A 1991; 88: 8840-4. (Pubitemid 21915451)
61. Inglehearn CF, Keen TJ, Bashir R, Jay M, Fitzke F, Bird AC, et al. A completed screen for mutations of the rhodopsin gene in a panel of patients with autosomal dominant retinitis pigmentosa. Hum Mol Genet 1992; 1: 41-5.
62. Bunge S, Wedemann H, David D, Terwilliger DJ, van den Born LI, Aulehla-Scholz C, et al. Molecular analysis and genetic mapping of the rhodopsin gene in families with autosomal dominant retinitis pigmentosa. Genomics 1993; 17: 230-3. (Pubitemid 23205084)
63. Kranich H, Bartkowski S, Denton MJ, Krey S, Dickinson P, Duvigneau C, et al. Autosomal dominant 'sector' retinitis pigmentosa due to a point mutation predicting an Asn-15-Ser substitution of rhodopsin. Hum Mol Genet 1993; 2: 813-4. (Pubitemid 23197533)
64. Chuang JZ, Vega C, Jun W, Sung CH. Structural and functional impairment of endocytic pathways by retinitis pigmentosa mutant rhodopsinarrestin complexes. J Clin Invest 2004; 114: 131-40. (Pubitemid 39071652)
65. Scott KM, Sieving PA, Bingham E, Bhagat VJ, Sullivan J, Alpern M, et al. Rhodopsin mutations associated with autosomal dominant retinitis pigmentosa. Am J Hum Genet 1993; 53: 147.
66. Li Y, Lambert MH, Xu HE. Activation of nuclear receptors: a perspective from structural genomics. Structure 2003; 11: 741-6. (Pubitemid 36830841)
67. Jacobson KA, Gao ZG, Liang BT. Neoceptors: reengineering GPCRs to recognize tailored ligands. Trends Pharmacol Sci 2007; 28: 111-6. (Pubitemid 46283591)
68. Costanzi S. On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor. J Med Chem 2008; 51: 2907-14. (Pubitemid 351706019)
69. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, et al. Ligand binding and co-activator assembly of the peroxisome proliferator- activated receptor-gamma. Nature 1998; 395: 137-43. (Pubitemid 28425645)
70. Cronet P, Petersen JF, Folmer R, Blomberg N, Sjoblom K, Karlsson U, et al. Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure 2001; 9: 699-706. (Pubitemid 32772892)
71. Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, et al. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A 2001; 98: 13919-24. (Pubitemid 33115999)